Anixa biosciences treats sixth patient in its ovarian cancer car-t clinical trial

This patient is expected to be the final patient in the second dosage cohort of the trial san jose, calif. , june 24, 2024 /prnewswire/ -- anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has treated the sixth patient in the ongoing phase 1 clinical trial of its novel chimeric antigen receptor t-cell (car-t) therapy for ovarian cancer.
CAR Ratings Summary
CAR Quant Ranking